Bartimus Frickleton Robertson Rader is investigating whether Bayer and Johnson & Johnson, the manufacturers of Xarelto, withheld vital information from users, doctors and regulators regarding the safety, efficacy and risks of the drug.
Xarelto is part of a class of drugs called New Oral Anticoagulants (NOACs) that make up the newest group of blood-thinning drugs. Xarelto was designed to replace Warfarin, which has been the standard therapy for the prevention of thrombosis and thromboembolism, the formation of blood clots in the blood vessels and their migration elsewhere in the body.
Blood-thinning drugs such as Warfarin require doctors to prescribe specific doses for each individual and then stringently monitor the level of anticoagulation in patients. This type of routine monitoring ensures that the drug was successfully thinning the blood enough to reduce the risk of a stroke, yet not so much as to create a risk of bleeding. This balance is referred to as the therapeutic range or window. Unlike older anticoagulants, Xarelto belongs to a new type of oral anticoagulant and claims it can be prescribed safely in one uniform dose and without the need for monitoring.
Also, while all blood thinners carry the risk of internal bleeding, older drugs like Warfarin have emergency antidotes to prevent serious harm. Xarelto, however, does not have an antidote, and the drug cannot be flushed out of the system through dialysis. People who suffer bleeding can end up hospitalized, and the bleeding may in some cases be fatal.
In its most important clinical trial, Xarelto was shown to cause a number of major bleeds in those people tested. Despite being aware of these adverse events, the makers of Xarelto may have withheld some crucial information from patients, doctors and regulators. A Xarelto lawsuit has been filed alleging this misconduct against Johnson & Johnson and Bayer.
These lawsuits claim these defendant companies concealed important safety information and failed to test drug adequately before it was put on the market.
If you have suffered major bleeding after taking Xarelto, please contact Bartimus Frickleton Robertson Rader today. You may be able to file a lawsuit for compensation.